SVRA
Savara Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.37
+0.00%Aug 24, 2026, 20:05 UTC
Savara Inc. announced that data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis will be presented at the ERS Congress 2026 in Barcelona, Spain, September 5-9, 2026.
Source:Jun 30, 2026, 00:00 UTC
Matthew Pauls was appointed as a Class I director of Palvella Therapeutics, Inc.
Jun 27, 2026, 15:34 UTC
David Lowrance, CFO of Savara, exercised 580,187 options on Common Stock and sold 394,528 shares in the open market on June 22, 2026.
Source:Jun 8, 2026, 20:05 UTC
Savara Inc. announced that Dave Lowrance will step down as Chief Financial and Administrative Officer effective July 15, 2026, and Robert Lutz will assume the combined role of Chief Operating and Financial Officer.
Source: